FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Cambridge, MA – September 30, 2015 – Intellia Therapeutics has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
"We're honored to be named to the 2015 "Fierce 15" Biotech Companies ranking and be recognized among other companies in the industry," said Nessan Bermingham, PhD, CEO & Founder, Intellia Therapeutics. "CRISPR/Cas9 is a breakthrough technology that has the potential to cure people living with life-threatening diseases. As a leading gene-editing company, Intellia is highly focused on advancing the science and we are on a critical path to achieving our mission to transform medicine for patients."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's thirteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online at www.fiercebiotech.com/fierce15.
An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Intellia Therapeutics
Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Intellia intends to advance its pipeline and potentially develop a new drug class by leveraging its leading scientific and clinical development expertise and its exclusive access to one of the most comprehensive intellectual property platforms available. Intellia is supported by its founding investors Atlas and Novartis, as well a number of public and private sector funds. In 2014, Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Jennifer Mound Smoter
Chief External Affairs & Communications Officer